InPlay: DuPont: wew DuPont molecular markers increase soybean productivity (Briefing.com)

10:50AM pSivida announces interim results from the three-month readout of the human PK Medidur FA study 2.60 +1.65 : Co reports the interim three-month safety and efficacy results from the first human pharmacokinetic study of Medidur FA, in patients with Diabetic Macular Edema. This Phase II study is designed to support the ongoing pivotal Phase III clinical trial of Medidur in Diabetic Macular Edema. The three month interim readout from the PK study indicated 20% of the low dose patients and 18% of the high dose patients showed an improvement in best-corrected visual acuity of 15 letters or greater from baseline on an eye chart. In addition, both the low dose and the high dose of Medidur resulted in a significant reduction in retinal thickness as compared to the baseline. From a safety perspective, no adverse events related... [read full story]